These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12395741)

  • 1. [Anti-inflammatory non-steroidal selective cyclooxygenase 2 inhibitors and gastroduodenal lesions].
    Bannwarth B
    Presse Med; 2002 Sep; 31(31):1469-75. PubMed ID: 12395741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Selective COX-2 inhibitors: do they retain any gastroduodenal toxicity].
    Bannwarth B
    Gastroenterol Clin Biol; 2004 Apr; 28 Spec No 3():C90-5. PubMed ID: 15366680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
    Naesdal J; Wilson I
    Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
    Lanas A
    Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in managing NSAID-associated gastrointestinal tract injury.
    Goldstein JL
    Digestion; 2004; 69 Suppl 1():25-33. PubMed ID: 15001832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy.
    Iwamoto J; Saito Y; Honda A; Matsuzaki Y
    World J Gastroenterol; 2013 Mar; 19(11):1673-82. PubMed ID: 23555156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
    Limmer S; Ittel TH; Wietholtz H
    Z Gastroenterol; 2003 Aug; 41(8):719-28. PubMed ID: 12910426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.
    Lanas A; García-Rodríguez LA; Arroyo MT; Gomollón F; Feu F; González-Pérez A; Zapata E; Bástida G; Rodrigo L; Santolaria S; Güell M; de Argila CM; Quintero E; Borda F; Piqué JM;
    Gut; 2006 Dec; 55(12):1731-8. PubMed ID: 16687434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention.
    Ballinger A; Smith G
    Expert Opin Pharmacother; 2001 Jan; 2(1):31-40. PubMed ID: 11336566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-steroidal anti-inflammatory drug gastropathy: causes and treatment.
    Hawkey CJ
    Scand J Gastroenterol Suppl; 1996; 220():124-7. PubMed ID: 8898449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current perspective on the cardiovascular effects of coxibs.
    Konstam MA; Weir MR
    Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One hundred years of NSAID gastropathy: are coxibs the answer?
    Bjorkman DJ
    Rev Gastroenterol Disord; 2001; 1(3):121-7. PubMed ID: 12120179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
    Strand V
    Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety of specific cyclo-oxygenase 2 inhibitors].
    Lems WF; van de Laar MA; Bijlsma JW
    Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1044-7. PubMed ID: 11414163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    ;
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
    Spiegel BM; Targownik L; Dulai GS; Gralnek IM
    Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.